Now showing items 1-6 of 6
Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries
Objective: Whilst dopaminergic dysfunction remains a necessary component involved in the pathogenesis of schizophrenia, our current pharmacological armoury of dopamine antagonists does little to control the negative ...
Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties
Aims: The phenothiazinium compound, methylene blue (MB), possesses diverse pharmacological actions and is attracting attention for the treatment of bipolar disorder and Alzheimer's disease. MB acts on both monoamine oxidase ...
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia
Background: While antipsychotics are effective in the maintenance treatment of schizophrenia they have safety and tolerability risks. We investigated whether a combination of omega-3 polyunsaturated fatty acids (ω−3 ...
Blunted neuro-endocrine responses linking depressive symptoms and ECG left ventricular hypertrophy in black Africans: the SABPA study
(Wolters Kluwer, 2014)
Objective: Chronic psychosocial stress as experienced in an urban environment plays an important role in the aetiology of depression-related cardiovascular risk. It is uncertain whether acute mental stress responses aggravate ...
New insights on the antidepressant discontinuation syndrome
Objective Antidepressants are at best 50–55% effective. Non-compliance and the antidepressant discontinuation syndrome (ADS) are causally related yet poorly appreciated. While ADS is associated with most antidepressants, ...
The interactions of azure B, a metabolite of methylene blue, with 2 acetylcholinesterase and butyrylcholinesterase
Methylene blue(MB) is reported to possess diverse pharmacological actions and is attracting increasing attention for the treatment of neurodegenerative disorders such as Alzheimer's disease. Among the pharmacological actions ...